500 milligram versions of Cubicin (daptomycin for injection) are being recalled by the Lexington, Massachusetts-based Cubist Pharmaceuticals due to concerns about the possibility of particulate matter within the injections. If a patient is exposed to some type of glass particulate, they could suffer from such things as an embolism, phlebitis, granulomas, and more. A supplier manufacturing problem is thought to be the cause of the particulate formation. No issues have come to light at this time, but those with the four affected lots in question are being asked not to administer the products. Instead, Cubist can be contacted for instructions on how to bring back the injections.
For more about the recall, click here.